歡迎來(lái)到上海谷研實(shí)業(yè)有限公司網(wǎng)站！
咨詢電話：18321818584歡迎來(lái)到上海谷研實(shí)業(yè)有限公司網(wǎng)站！咨詢電話：18321818584
簡(jiǎn)要描述：補(bǔ)體C3抗體注意事項(xiàng)；This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品型號(hào)：GOY-01K0119廠商性質(zhì)：科研更新時(shí)間：2023-10-24 00:00:00訪 問(wèn) 量：172產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
商品屬性：
貨號(hào) | 產(chǎn)品名稱 | 規(guī)格 |
GOY-01K0119 | 補(bǔ)體C3抗體 | 50ul |
GOY-01K0119 | 補(bǔ)體C3抗體 | 100ul |
GOY-01K0119 | 補(bǔ)體C3抗體 | 200ul |
英文名稱: Complement C3
中文名稱: 補(bǔ)體C3抗體
別 名；Acylation stimulating protein cleavage
product; Acylation-stimulating protein cleavage product; AHUS5; ARMD9; ASP;
ASP; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody
C3 antibody C3a anaphylatoxin; CO3_HUMAN; Complement C3 alpha chain; Complement
C3; Complement C3 beta chain; Complement C3 precursor; Complement C3b alpha
chain; Complement C3c alpha' chain fragment 2; Complement C3c fragment;
Complement C3d fragment; Complement C3f fragment; Complement C3g fragment;
Complement component 3; Complement component 3 precursor; Complement component
C3; Complement factor 3; CPAMD1; Plp.
研究領(lǐng)域；細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué)
抗體來(lái)源；Goat
克隆類型；Polyclonal
交叉反應(yīng)； (predicted: Human, )
產(chǎn)品應(yīng)用；ELISA=1:5000-10000
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量；187kDa
細(xì)胞定位；分泌型蛋白
性 狀；Liquid
濃 度；1mg/ml
免 疫 原；human Complement C3 purified
from human plasma: full length
亞 型；IgG
純化方法；affinity purified by Protein A
緩 沖 液；0.01M TBS(pH7.4) with 1% BSA,
0.03% Proclin300 and 50% Glycerol.
注意事項(xiàng)；This product as supplied is
intended for research use only, not for use in human, therapeutic or diagnostic
applications.
產(chǎn)品介紹 The complement factor C3
consists of an alpha and a beta chain. C3 is a central factor in the complement
cascade. It is central to the alternative pathway that leads to the C3
convertase C3bBb. The classical mannose binding lectin activation pathway leads
to the C3 convertase C4b2a. These convertases cleave C3 resulting in C3a and
C3b. Further degradation leads to the formation of the alpha chain products
C3d, C3g and C3c. C3 is an acute phase protein that is produced by a wide range
of tissues, including renal epithelial cells and hepatocytes.
C3 plays a central
role in the activation of the complement system. Its processing by C3
convertase is the central reaction in both classical and alternative complement
pathways. After activation C3b can bind covalently, via its reactive thioester,
to cell surface carbohydrates or immune aggregates.
Derived from
proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of
local inflammatory process. It induces the contraction of smooth muscle,
increases vascular permeability and causes histamine release from mast cells
and basophilic leukocytes.
Acylation stimulating protein (ASP): adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for GPR77. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of GPR77.
實(shí)驗(yàn)流程：
（1）特異性結(jié)合抗原：抗體本身不能直接溶解或殺傷帶有特異抗原的靶細(xì)胞，通常需要補(bǔ)體或吞噬細(xì)胞等共同發(fā)揮效應(yīng)以清除病原微生物或?qū)е虏±頁(yè)p傷。然而，抗體可通過(guò)與病毒或毒素的特異性結(jié)合，直接發(fā)揮中和病毒的作用。
（2）活補(bǔ)體：IgM、IgG1、IgG2和IgG3可通過(guò)經(jīng)典途徑激活補(bǔ)體，凝聚的IgA、IgG4和IgE可通過(guò)替代途徑激活補(bǔ)體。
（3）結(jié)合細(xì)胞：不同類別的免疫球蛋白，可結(jié)合不同種的細(xì)胞，參與免疫應(yīng)答。
（4）可通過(guò)胎盤(pán)及粘膜：免疫球蛋白G（IgG）能通過(guò)胎盤(pán)進(jìn)入胎兒血流中，使胎兒形成自然被動(dòng)
免疫。免疫球蛋白A（IgA）可通過(guò)消化道及呼吸道粘膜，是粘膜局部抗感染免疫的主要因素。
（5）具有抗原性：抗體分子是一種蛋白質(zhì)，也具有刺機(jī)體產(chǎn)生免疫應(yīng)答的性能。不同的免疫球蛋白分子，各具有不同的抗原性。
（6）抗體對(duì)理化因子的抵抗力與一般球蛋白相同：不耐熱，60～70℃即被破壞。各種酶及能使蛋白質(zhì)凝固變性的物質(zhì)，均能破壞抗體的作用?？贵w可被中性鹽類沉淀。在生產(chǎn)上?？捎昧蛩徜@或硫酸鈉從免疫血清中沉淀出含有抗體的球蛋白，再經(jīng)透析法將其純化。
抗體的制備過(guò)程：
1.免疫原：普通的大分子蛋白，通過(guò)分子克隆構(gòu)建載體并在大腸桿菌中進(jìn)行誘導(dǎo)表達(dá)獲得重組蛋白，純化鑒定后可直接作為免疫原；小分子蛋白或化合物等分子量小，需要偶聯(lián)載體對(duì)該分子進(jìn)行改造才能使其成為具有免疫原性的抗原，常見(jiàn)偶聯(lián)載體如BSA、OVA、HAS等。
2. 免疫動(dòng)物：常用于制備抗血清的動(dòng)物有豚鼠、家兔、雞、大小鼠等，大量生產(chǎn)時(shí)需要用到狗、綿羊、山羊等。
3.免疫血清的收集：一般家兔、綿羊、山羊可采用靜動(dòng)脈采血，家兔、豚鼠、大鼠、雞可采用心臟采血，家兔、山羊、綿羊可采用靜脈采血。
4. 免疫血清的純化與鑒定：得到的抗血清需要進(jìn)一步的純化，利用偶聯(lián)了抗原的親和柱進(jìn)行層析，具有高效，特異性強(qiáng)，純度高的特定。接著要鑒定純化蛋白的含量、相對(duì)分子的質(zhì)量、純度以及特異性。
5.補(bǔ)體C3抗體免疫血清的保存：抗體一般比較穩(wěn)定，在-80℃ ～-20 ℃可以保存約5年而不會(huì)影響效價(jià)，而真空干燥保存時(shí)間可以更久。保存前需經(jīng)除菌并添加防腐劑。
產(chǎn)品咨詢
聯(lián)系人：銷售部
地址：上海市嘉定區(qū)澄瀏公路52號(hào)盛創(chuàng)企業(yè)
郵箱：3004918891@qq.com
手機(jī)：18321818584 / 15026555973歡迎您關(guān)注我們的微信了解更多信息
掃一掃電話
微信掃一掃